Gli ultimi sviluppi della ricerca, aggiornamenti sugli studi clinici e notizie normative dalla comunità scientifica dei peptidi.
Lean mass loss is an increasingly important endpoint in GLP-1 class drug research. We review the current data on what proportion of weight lost is fat vs muscle, and what the research implications are for combination approaches.
The combination of a GHRH analogue and a GHRP creates a synergistic GH secretagogue profile that neither compound achieves alone. We examine the mechanistic rationale and what preclinical combination data shows for CJC-1295 and Ipamorelin.
With semaglutide and tirzepatide now mainstream, the research community has turned its focus to longer-acting, more selective, and multi-receptor peptide agonists. We map the current frontier.
Tutti i contenuti sono esclusivamente a scopo scientifico ed educativo. I peptidi di ricerca sono destinati solo all'uso in laboratorio e non al consumo umano.
